AI주식인사이트AI Stock Insight
C

경동제약

011040KOSDAQ의약품 제조업

48.3 / 100

Reference Date: 2026-04-13

Financial Score20.5 / 40
News Sentiment10.8 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Roughly flat over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Gyeongdong Pharmaceutical, established in 1976, is a company specializing in the manufacturing and sales of pharmaceuticals. Its business segments include pharmaceuticals (accounting for ~95% of sales), leasing, and others. Key products include DuoLoban tablets and Alpotin soft capsules, targeting rising demand due to aging populations and Western dietary habits. The company is expanding exports and developing new products, including OTC drugs and health supplements.

Number of Employees

363people

Average Salary

56.0M KRW

Score Calculation Basis

Detailed Financial Score

PER
17.31Industry Average 14.803.0Point

Higher than industry avg (caution)

PBR
0.74Industry Average 1.045.5Point

Lower than industry avg (good)

ROE
3.76Industry Average 4.422.5Point

Below industry avg

Debt Ratio
10.24Industry Average 11.984.0Point

In line with industry avg

Trend 2023~20255.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲10.2% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲151.4% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -0.8% (improving, 3yr)

Detailed News Sentiment

3 totalPositive 0Neutral 2Negative 0Average Sentiment Score 40

Detailed Momentum

52-week position1.0Point

Near 52w low (19%, downtrend)

Current 5,470Won52-week high 6,20052-week low 5,290
1-month return3.0Point

1m 0% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-04-03
  • Neutral정기주주총회결과2026-03-30
  • Neutral기업가치제고계획(자율공시)2026-03-30
  • Neutral감사보고서제출2026-03-20
  • Neutral사업보고서 (2025.12)2026-03-20